NCT00755287

Brief Summary

This 3-arm study will assess the efficacy, safety and tolerability of taspoglutide compared to insulin glargine in patients with insulin-naive type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea combination therapy. Patients will be randomized to receive taspoglutide (10 mg once weekly, or 10mg once weekly for 4 weeks followed by 20mg once weekly) or insulin glargine (starting dose 10 IU/day) in a ratio of 1:1:1 in addition to continued prestudy metformin treatment. The anticipated time on study treatment is 2+ years, and the target sample size if 500+ individuals.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
1,072

participants targeted

Target at P75+ for phase_3 diabetes-mellitus-type-2

Timeline
Completed

Started Nov 2008

Typical duration for phase_3 diabetes-mellitus-type-2

Geographic Reach
26 countries

205 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 17, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 18, 2008

Completed
1 month until next milestone

Study Start

First participant enrolled

November 1, 2008

Completed
2.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
Last Updated

July 29, 2016

Status Verified

July 1, 2016

Enrollment Period

2.1 years

First QC Date

September 17, 2008

Last Update Submit

July 27, 2016

Conditions

Outcome Measures

Primary Outcomes (1)

  • Absolute change from baseline in HbA1c

    24 weeks

Secondary Outcomes (3)

  • Change from baseline in fasting plasma glucose; change from baseline in body weight; responder rates for HbA1c (target <=7.0%, <=6.5%); incidence of hypoglycemia; change from baseline in lipid profile.

    24 weeks

  • Relative change in glucose, insulin, C-peptide and glucagon during a meal tolerance test.

    24 weeks

  • Safety: Adverse events, vital signs, physical examination, clinical laboratory tests, ECG and anti-taspoglutide antibodies

    Throughout study

Study Arms (3)

insulin glargine

ACTIVE COMPARATOR

insulin glargine starting dose 10 IU daily in addition to continued prestudy metformin treatment

Drug: insulin glargineDrug: metformin

taspoglutide 10 mg

EXPERIMENTAL

taspoglutide 10 mg once weekly in addition to continued prestudy metformin treatment

Drug: metforminDrug: taspoglutide

taspoglutide 10 mg/20 mg

EXPERIMENTAL

taspoglutide 20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly) in addition to continued prestudy metformin treatment

Drug: metforminDrug: taspoglutide

Interventions

starting dose 10 IU daily

insulin glargine

As prescribed

insulin glarginetaspoglutide 10 mgtaspoglutide 10 mg/20 mg

10 mg once weekly

taspoglutide 10 mg

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • adult patients, 18-75 years of age;
  • type 2 diabetes treated with a stable dose of metformin and sulphonylurea for at least 12 weeks;
  • C-peptide (fasting) \>=1.0ng/mL;
  • HbA1c \>=7.0% and \<=10.0% at screening;
  • BMI \>=25 (\>23 for Asians) and \<=45kg/m2 at screening;
  • stable weight +-5% for at least 12 weeks prior to screening.

You may not qualify if:

  • history of type 1 diabetes mellitus or acute metabolic diabetic complications such as ketoacidosis or hyperosmolar coma in the previous 6 months;
  • evidence of clinically significant diabetic complications;
  • symptomatic poorly controlled diabetes;
  • clinically symptomatic gastrointestinal disease;
  • myocardial infarction, coronary artery bypass surgery, post-transplantation cardiomyopathy or stroke within the previous 6 months;
  • known hemoglobinopathy or chronic anemia.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (210)

Unknown Facility

Phoenix, Arizona, 85032, United States

Location

Unknown Facility

Searcy, Arkansas, 72143, United States

Location

Unknown Facility

Concord, California, 94520, United States

Location

Unknown Facility

Huntington Beach, California, 92648, United States

Location

Unknown Facility

Los Angeles, California, 90015, United States

Location

Unknown Facility

Los Angeles, California, 90025, United States

Location

Unknown Facility

Los Gatos, California, 95032, United States

Location

Unknown Facility

Roseville, California, 95661, United States

Location

Unknown Facility

San Diego, California, 92109, United States

Location

Unknown Facility

Santa Ana, California, 92705, United States

Location

Unknown Facility

Westlake Village, California, 91361, United States

Location

Unknown Facility

Washington D.C., District of Columbia, 20010, United States

Location

Unknown Facility

Green Cove Springs, Florida, 32043, United States

Location

Unknown Facility

Hialeah, Florida, 33013, United States

Location

Unknown Facility

Jacksonville, Florida, 32204, United States

Location

Unknown Facility

Jacksonville, Florida, 32216, United States

Location

Unknown Facility

Ormond Beach, Florida, 32174, United States

Location

Unknown Facility

Oviedo, Florida, 32765, United States

Location

Unknown Facility

Palm Harbor, Florida, 34684, United States

Location

Unknown Facility

Trinity, Florida, 34655, United States

Location

Unknown Facility

Zephyrhills, Florida, 33542, United States

Location

Unknown Facility

Atlanta, Georgia, 30338, United States

Location

Unknown Facility

Quincy, Illinois, 62301, United States

Location

Unknown Facility

Springfield, Illinois, 62704-1433, United States

Location

Unknown Facility

Avon, Indiana, 46123, United States

Location

Unknown Facility

Indianapolis, Indiana, 46260, United States

Location

Unknown Facility

Arkansas City, Kansas, 67005, United States

Location

Unknown Facility

Crestview Hills, Kentucky, 41017, United States

Location

Unknown Facility

Metairie, Louisiana, 70006, United States

Location

Unknown Facility

Sunset, Louisiana, 70584, United States

Location

Unknown Facility

Portland, Maine, 04101, United States

Location

Unknown Facility

North East, Maryland, 21901, United States

Location

Unknown Facility

Worchester, Massachusetts, 01605, United States

Location

Unknown Facility

Saint Claire Shores, Michigan, 48081, United States

Location

Unknown Facility

Jackson, Mississippi, 39216, United States

Location

Unknown Facility

Picayune, Mississippi, 39466, United States

Location

Unknown Facility

Springfield, Missouri, 65807, United States

Location

Unknown Facility

Grand Island, Nebraska, 68803, United States

Location

Unknown Facility

Omaha, Nebraska, 68105, United States

Location

Unknown Facility

Omaha, Nebraska, 68131, United States

Location

Unknown Facility

Henderson, Nevada, 89014, United States

Location

Unknown Facility

Blackwood, New Jersey, 08012, United States

Location

Unknown Facility

Cherry Hill, New Jersey, 08002, United States

Location

Unknown Facility

Moorestown, New Jersey, 08057, United States

Location

Unknown Facility

Toms River, New Jersey, 08753, United States

Location

Unknown Facility

Toms River, New Jersey, 08755, United States

Location

Unknown Facility

Albany, New York, 12206-1098, United States

Location

Unknown Facility

Flushing, New York, 11365, United States

Location

Unknown Facility

Mineola, New York, 11501, United States

Location

Unknown Facility

Asheville, North Carolina, 28803, United States

Location

Unknown Facility

Harrisburg, North Carolina, 28075, United States

Location

Unknown Facility

Fargo, North Dakota, 58103, United States

Location

Unknown Facility

Centerville, Ohio, 45459, United States

Location

Unknown Facility

Cincinnati, Ohio, 45242, United States

Location

Unknown Facility

Genoa, Ohio, 43430-1143, United States

Location

Unknown Facility

Toledo, Ohio, 43606, United States

Location

Unknown Facility

Altoona, Pennsylvania, 16602, United States

Location

Unknown Facility

Bensalem, Pennsylvania, 19020, United States

Location

Unknown Facility

Feasterville, Pennsylvania, 19053, United States

Location

Unknown Facility

Harrisburg, Pennsylvania, 17112, United States

Location

Unknown Facility

Jefferson Hills, Pennsylvania, 15025, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19107, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19146, United States

Location

Unknown Facility

Scranton, Pennsylvania, 18510, United States

Location

Unknown Facility

Tipton, Pennsylvania, 16684, United States

Location

Unknown Facility

Orangeburg, South Carolina, 29115, United States

Location

Unknown Facility

Johnson City, Tennessee, 37604, United States

Location

Unknown Facility

Dallas, Texas, 75230, United States

Location

Unknown Facility

Dallas, Texas, 75246, United States

Location

Unknown Facility

Dallas, Texas, 75390, United States

Location

Unknown Facility

Houston, Texas, 77024, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Richmond, Virginia, 23249, United States

Location

Unknown Facility

Waukesha, Wisconsin, 53189, United States

Location

Unknown Facility

St Leonards, New South Wales, 2065, Australia

Location

Unknown Facility

Wollongong, New South Wales, 2500, Australia

Location

Unknown Facility

Freemantle, Queensland, 6959, Australia

Location

Unknown Facility

Graz, 8036, Austria

Location

Unknown Facility

Salzburg, 5020, Austria

Location

Unknown Facility

Vienna, 1030, Austria

Location

Unknown Facility

Vienna, 1080, Austria

Location

Unknown Facility

Vienna, 1130, Austria

Location

Unknown Facility

Arlon, 6700, Belgium

Location

Unknown Facility

Bonheiden, 2820, Belgium

Location

Unknown Facility

Leuven, 3000, Belgium

Location

Unknown Facility

Liège, 4000, Belgium

Location

Unknown Facility

Campina Grande do Sul, Paraná, 83430-000, Brazil

Location

Unknown Facility

Curitiba, Paraná, 80030-110, Brazil

Location

Unknown Facility

Recife, Pernambuco, 52051-380, Brazil

Location

Unknown Facility

Porto Alegre, Rio Grande do Sul, 90035-170, Brazil

Location

Unknown Facility

São Paulo, São Paulo, 04022-001, Brazil

Location

Unknown Facility

Vancouver, British Columbia, V5Z 1L8, Canada

Location

Unknown Facility

Hamilton, Ontario, L8S 4J9, Canada

Location

Unknown Facility

London, Ontario, N6A 5R8, Canada

Location

Unknown Facility

Toronto, Ontario, M5G 2C4, Canada

Location

Unknown Facility

Pointe-Claire, Quebec, H9R 4S3, Canada

Location

Unknown Facility

Sherbrooke, Quebec, J1G 5K2, Canada

Location

Unknown Facility

Brno, 625 00, Czechia

Location

Unknown Facility

Havířov, 76301, Czechia

Location

Unknown Facility

Pilsen, 301 00, Czechia

Location

Unknown Facility

Prague, 180 00, Czechia

Location

Unknown Facility

Trutnov, 541 01, Czechia

Location

Unknown Facility

Helsinki, 00150, Finland

Location

Unknown Facility

Jyväskylä, 40100, Finland

Location

Unknown Facility

Tampere, 33100, Finland

Location

Unknown Facility

Avignon, 84902, France

Location

Unknown Facility

Besançon, 25030, France

Location

Unknown Facility

Bois-Guillaume, 76233, France

Location

Unknown Facility

Brest, 29609, France

Location

Unknown Facility

Corbeil-Essonnes, 91106, France

Location

Unknown Facility

La Rochelle, 17019, France

Location

Unknown Facility

Marseille, 13015, France

Location

Unknown Facility

Marseille, 13385, France

Location

Unknown Facility

Montpellier, 34295, France

Location

Unknown Facility

Nîmes, 30029, France

Location

Unknown Facility

Paris, 75651, France

Location

Unknown Facility

Paris, 75877, France

Location

Unknown Facility

Paris, 75908, France

Location

Unknown Facility

Strasbourg, 67091, France

Location

Unknown Facility

Vénissieux, 69200, France

Location

Unknown Facility

Bad Lauterberg im Harz, 37431, Germany

Location

Unknown Facility

Berlin, 10115, Germany

Location

Unknown Facility

Bochum, 44869, Germany

Location

Unknown Facility

Bosenheim, 55545, Germany

Location

Unknown Facility

Dortmund, 44137, Germany

Location

Unknown Facility

Falkensee, 14612, Germany

Location

Unknown Facility

Freiburg im Breisgau, 79106, Germany

Location

Unknown Facility

Mainz, 55116, Germany

Location

Unknown Facility

Offenbach a.M., 63065, Germany

Location

Unknown Facility

Reichenbach, 08468, Germany

Location

Unknown Facility

Würzburg, 97072, Germany

Location

Unknown Facility

Athens, 10552, Greece

Location

Unknown Facility

Larissa, 41110, Greece

Location

Unknown Facility

Thessaloniki, 56429, Greece

Location

Unknown Facility

Guatemala City, 01010, Guatemala

Location

Unknown Facility

Hong Kong, Hong Kong

Location

Unknown Facility

Balatonfüred, 8230, Hungary

Location

Unknown Facility

Budapest, 1045, Hungary

Location

Unknown Facility

Szekszárd, 7100, Hungary

Location

Unknown Facility

Napoli, Campania, 80100, Italy

Location

Unknown Facility

Rome, Lazio, 00157, Italy

Location

Unknown Facility

Codogno, Lombardy, 26845, Italy

Location

Unknown Facility

Milan, Lombardy, 20132, Italy

Location

Unknown Facility

Milan, Lombardy, 20142, Italy

Location

Unknown Facility

Turin, Piedmont, 10126, Italy

Location

Unknown Facility

Aguascalientes, 20127, Mexico

Location

Unknown Facility

Cuernavaca, 62250, Mexico

Location

Unknown Facility

Monterrey, 64410, Mexico

Location

Unknown Facility

Tampico, 89000, Mexico

Location

Unknown Facility

Auckland, 1640, New Zealand

Location

Unknown Facility

Auckland, New Zealand

Location

Unknown Facility

Arequipa, Cercado, Peru

Location

Unknown Facility

Lima, Lima 1, Peru

Location

Unknown Facility

Lima, Lima 33, Peru

Location

Unknown Facility

Trujillo, 13011, Peru

Location

Unknown Facility

Grodzisk Mazowiecki, 05-825, Poland

Location

Unknown Facility

Kamieniec Ząbkowicki, 57-230, Poland

Location

Unknown Facility

Lodz, 93-338, Poland

Location

Unknown Facility

Rzeszów, 35-073, Poland

Location

Unknown Facility

Sobótka, 55-050, Poland

Location

Unknown Facility

Szczecin, 71-455, Poland

Location

Unknown Facility

Wroclaw, 51-124, Poland

Location

Unknown Facility

Coimbra, 3000-075, Portugal

Location

Unknown Facility

Lisbon, 1250-203, Portugal

Location

Unknown Facility

Lisbon, 1349-019, Portugal

Location

Unknown Facility

Guyanabo, San Juan, 00920, Puerto Rico

Location

Unknown Facility

Levittown, 00950, Puerto Rico

Location

Unknown Facility

Orocovis, 00720, Puerto Rico

Location

Unknown Facility

Ponce, 00717-322, Puerto Rico

Location

Unknown Facility

San Juan, 00926-2832, Puerto Rico

Location

Unknown Facility

Trujillo Alto, 00976, Puerto Rico

Location

Unknown Facility

Barnaul, 656024, Russia

Location

Unknown Facility

Chelyabinsk, 454136, Russia

Location

Unknown Facility

Moscow, 117049, Russia

Location

Unknown Facility

Moscow, 125299, Russia

Location

Unknown Facility

Moscow, 129110, Russia

Location

Unknown Facility

Nizhny Novgorod, 603126, Russia

Location

Unknown Facility

Novosibirsk, 630047, Russia

Location

Unknown Facility

Omsk, 644021, Russia

Location

Unknown Facility

Saint Petersburg, 193012, Russia

Location

Unknown Facility

Saint Petersburg, 194291, Russia

Location

Unknown Facility

Saint Petersburg, 194354, Russia

Location

Unknown Facility

Saint Petersburg, 195213, Russia

Location

Unknown Facility

Saint Petersburg, 197022, Russia

Location

Unknown Facility

Tomsk, 643050, Russia

Location

Unknown Facility

Belgrade, 11000, Serbia

Location

Unknown Facility

Kragujevac, 34000, Serbia

Location

Unknown Facility

Niš, 18000, Serbia

Location

Unknown Facility

Novi Sad, 21000, Serbia

Location

Unknown Facility

Daegu, 700-721, South Korea

Location

Unknown Facility

Incheon, South Korea

Location

Unknown Facility

Seoul, 137-040, South Korea

Location

Unknown Facility

Almería, Almeria, 04001, Spain

Location

Unknown Facility

Barcelona, Barcelona, 08025, Spain

Location

Unknown Facility

Granada, Granada, 18012, Spain

Location

Unknown Facility

Pozuelo de Alarcón, Madrid, 28223, Spain

Location

Unknown Facility

Seville, Sevilla, 41010, Spain

Location

Unknown Facility

Seville, Sevilla, 41013, Spain

Location

Unknown Facility

Alzira, Valencia, 46600, Spain

Location

Unknown Facility

Valencia, Valencia, 46010, Spain

Location

Unknown Facility

Valencia, Valencia, 46014, Spain

Location

Unknown Facility

Valladolid, Valladolid, 47005, Spain

Location

Unknown Facility

Bangkok, 10330, Thailand

Location

Unknown Facility

Bangkok, 10400, Thailand

Location

Unknown Facility

Atherstone, CV9 1EU, United Kingdom

Location

Unknown Facility

Chesterfield, S40 4TF, United Kingdom

Location

Unknown Facility

Dumfries, DG1 4AP, United Kingdom

Location

Unknown Facility

Liverpool, L9 7AL, United Kingdom

Location

Unknown Facility

Sheffield, S18 1RU, United Kingdom

Location

Unknown Facility

Trowbridge, BA14 8QA, United Kingdom

Location

Related Publications (1)

  • Nauck M, Horton E, Andjelkovic M, Ampudia-Blasco FJ, Parusel CT, Boldrin M, Balena R; T-emerge 5 Study Group. Taspoglutide, a once-weekly glucagon-like peptide 1 analogue, vs. insulin glargine titrated to target in patients with Type 2 diabetes: an open-label randomized trial. Diabet Med. 2013 Jan;30(1):109-13. doi: 10.1111/dme.12003.

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

Insulin GlargineMetformintaspoglutide

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

Insulin, Long-ActingInsulinsPancreatic HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and ProteinsBiguanidesGuanidinesAmidinesOrganic Chemicals

Study Officials

  • Clinical Trials

    Hoffmann-La Roche

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 17, 2008

First Posted

September 18, 2008

Study Start

November 1, 2008

Primary Completion

December 1, 2010

Study Completion

December 1, 2010

Last Updated

July 29, 2016

Record last verified: 2016-07

Locations